Last reviewed · How we verify

Mitapivat coated granules

Agios Pharmaceuticals, Inc. · Phase 1 active Small molecule

Mitapivat coated granules is a Small molecule drug developed by Agios Pharmaceuticals, Inc.. It is currently in Phase 1 development. Also known as: AG-348, AG-348 sulfate hydrate, Mitapivat sulfate.

At a glance

Generic nameMitapivat coated granules
Also known asAG-348, AG-348 sulfate hydrate, Mitapivat sulfate
SponsorAgios Pharmaceuticals, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mitapivat coated granules

What is Mitapivat coated granules?

Mitapivat coated granules is a Small molecule drug developed by Agios Pharmaceuticals, Inc..

Who makes Mitapivat coated granules?

Mitapivat coated granules is developed by Agios Pharmaceuticals, Inc. (see full Agios Pharmaceuticals, Inc. pipeline at /company/agios-pharmaceuticals-inc).

Is Mitapivat coated granules also known as anything else?

Mitapivat coated granules is also known as AG-348, AG-348 sulfate hydrate, Mitapivat sulfate.

What development phase is Mitapivat coated granules in?

Mitapivat coated granules is in Phase 1.

Related